Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Trends in Screening for Colorectal Cancer-United States, 1997 and 1999

May 1, 2001
Publication
Article
OncologyONCOLOGY Vol 15 No 5
Volume 15
Issue 5

Colorectal cancer is the second leading cause of cancer-related death in the United States. An estimated 135,400 new cases and 56,700 deaths from colorectal cancer are expected during 2001. Since the mid-1990s, national guidelines have

Colorectal cancer is the second leadingcause of cancer-related death in the United States. An estimated 135,400 newcases and 56,700 deaths from colorectal cancer are expected during 2001. Sincethe mid-1990s, national guidelines have recommended that persons aged ³ 50years who are at average risk for colorectal cancer should have screening testsregularly. To estimate rates for the use of colorectal cancer screening testsand to evaluate trends in test use, the Centers for Disease Control andPrevention (CDC) analyzed data from the 1999 Behavioral Risk Factor SurveillanceSystem (BRFSS) on the use of a home-administered fecal occult blood test andsigmoidoscopy/colonoscopy, and then compared them with similar data from 1997.

The findings in this report indicate that the proportion of theUS population that has been screened remains low. In 1999, 44% of BRFSSrespondents reported receiving a fecal occult blood test and/orsigmoidoscopy/colonoscopy within the recommended period, compared withapproximately 41% reporting a fecal occult blood test and/orsigmoidoscopy/proctoscopy within the recommended period in 1997. Efforts toaddress barriers and to promote the use of colorectal cancer screening should beintensified.

Telephone Survey

In 1999, the 50 states, District of Columbia, and Puerto Ricoparticipated in BRFSS, an ongoing, state-based, random-digit-dialed telephonesurvey of the civilian, noninstitutionalized population aged ³ 18 years. Atotal of 63,555 respondents aged ³ 50 years were asked whether they ever had afecal occult blood test using a home kit, whether they ever had sigmoidoscopy orcolonoscopy, and when the last test had been performed. Responses coded as"don’t know/not sure" or "refused" were excluded fromanalyses (< 2%). Aggregated and state-specific proportions, standard errors,95% confidence intervals, and P values were calculated using SAS and SUDAANsoftware for statistical analysis.

Data in this analysis were weighted to the age, sex, andrace/ethnicity distribution of each state’s adult population using intercensalestimates and were age-standardized to the 1999 BRFSS population. The medianstate response rate of 56.7% (range: 38.4%-83.9%) was calculated using thecooperation rate formula (ie, the number of completed interviews divided by thenumber of potential respondents [households with a resident aged ³ 18 years]).The 1999 questions about the use of sigmoidoscopy were modified from the 1997questions.

In 1997, respondents were asked whether they had receivedsigmoidoscopy or proctoscopy. Proctoscopy is performed with a shorter instrumentthan sigmoidoscopy and is not recommended as a colorectal cancer screening test.In 1999, "sigmoidoscopy/proctoscopy" was replaced with"sigmoidoscopy/colonoscopy." Colonoscopy evaluates the entire colonand in some guidelines is recommended once every 10 years. For this report,"sigmoidoscopy/proctoscopy" and "sigmoidoscopy/colonoscopy"are referred to as "sigmoidoscopy" unless otherwise specified.

Less Than Half Undergo Screening

In 1999, 40.3% (25,263 of approximately 63,000) of respondentsreported ever having a fecal occult blood test, and 43.8% (26,388) of therespondents reported ever having sigmoidoscopy. For tests received within therecommended period, 20.6% (12,518) had a fecal occult blood test within the yearpreceding the survey, 33.6% (19,535) had sigmoidoscopy within the preceding 5years (Table 1). the proposition of respondents having either a fecal occultblood test within the year preceding the survey or sigmoidoscopy within thepreceding 5 years is shown in Figure 1.

In 1997, 19.6% (9,832 of approximately 51,000) of therespondents had a fecal occult blood test within the year preceding the survey,and 30.3% (14,678) had sigmoidoscopy within the preceding 5 years (Table1).Although these rate changes in testing use were statistically significant (P< .05), actual increases were small. By state, the proportion of respondentswho had a fecal occult blood test within the preceding year ranged from 8.2%(112 of 1,366) in Puerto Rico to 36.4% (187 of 500) in the District of Columbia;the proportion that had sigmoidoscopy/colonoscopy within the preceding 5 yearsranged from 20.4% (275 of 1,357) in Puerto Rico to 46.1% (410 of 981) inDelaware (Table 2).

Editorial Note From the CDC

Since 1997, the proportion of the US population that reportedhaving had a fecal occult blood test and sigmoidoscopy has increased slightlybut remains low. Various factors may contribute to the continued underuse ofthese tests, including lack of knowledge by the public and health-care providersof the effectiveness of screening and low reimbursement rates for health-careproviders who perform screening tests.

The findings in this report are subject to at least fourlimitations. First, because of the wording change in the BRFSS questionnairefrom "sigmoidoscopy/proctoscopy" in 1997 to"sigmoidoscopy/colonoscopy" in 1999, comparing endoscopic proceduresfor these years must be interpreted with caution. Data on the use of colonoscopywere collected only in 1999; however, some tests reported assigmoidoscopies/proctoscopies in 1997 probably were colonoscopies because somerespondents may have been unable to distinguish among the three tests. It isunknown whether the reported increase from 1997 to 1999 represents a trueincrease in sigmoidoscopy use or previously unmeasured rates of colonoscopy use.

Second, because the survey was administered over the telephone,only persons who own telephones were represented in this analysis. Third, 43.3%of the eligible respondents were contacted but did not complete the telephoneinterview or could not be reached for an interview. Finally, responses wereself-reported and were not validated through medical record review.

Recommended Screeningfor Those 50 Years and Older

For persons aged ³ 50 years at average risk for colorectalcancer, recommended screening options include one or more of the followingtests: Fecal occult blood test every year plus flexible sigmoidoscopy every 5years, annual fecal occult blood test, sigmoidoscopy every 5 years, double-contrast barium enema every 5 to 10 years, orcolonoscopy every 10 years. Despite their efficacy in reducing the incidence andmortality from colorectal cancer, screening tests are underused. To drawattention to this disease, the US Congress designated March as NationalColorectal Cancer Awareness Month. During March 2001, the CDC and the HealthCare Financing Administration launched the third annual Screen for Life: ANational Colorectal Cancer Action Campaign.

Using print, television, and radio announcements, as well asbrochures and fact sheets, the campaign was designed to raise awareness ofcolorectal cancer and to encourage persons aged ³ 50 years to discuss screeningwith their health-care provider and select the appropriate test(s). The CDC alsoproduced a slide presentation forhealth-care providers. All material is available on the Web at http://www.cdc.gov/cancer/screenforlife andhttp://www.cdc.gov/cancer/colorctl/calltoaction.

Articles in this issue

Current Therapy in Cancer, Second Edition
Health-Related Quality of Life in Cancer Clinical Trials
Paroxetine Reduces Distress Associated With Cancer Treatment
Another Attempt to Rein in Medicare
Tamoxifen for Breast Cancer Prevention Has No Heart-Related Effects
Exercise Benefits Patients Being Treated for Early-Stage Breast Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Related Content

Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 22nd 2025
Article

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
August 22nd 2025
Podcast

The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.

Low Dose-Averaged LET Exhibits Poor Local Control in Pancreatic Cancer

Roman Fabbricatore
August 22nd 2025
Article

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
August 22nd 2025
Podcast

Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.

Robotic Surgery Exhibits Benefit in Select Colorectal Cancer Procedures

Roman Fabbricatore
August 22nd 2025
Article

Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.

Sotorasib Combo Improves Patient-Reported Outcomes in KRAS G12C+ CRC

Russ Conroy
August 22nd 2025
Article
Related Content

Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 22nd 2025
Article

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
August 22nd 2025
Podcast

The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.

Low Dose-Averaged LET Exhibits Poor Local Control in Pancreatic Cancer

Roman Fabbricatore
August 22nd 2025
Article

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
August 22nd 2025
Podcast

Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.

Robotic Surgery Exhibits Benefit in Select Colorectal Cancer Procedures

Roman Fabbricatore
August 22nd 2025
Article

Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.

Sotorasib Combo Improves Patient-Reported Outcomes in KRAS G12C+ CRC

Russ Conroy
August 22nd 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.